Please login to the form below

Not currently logged in
Email:
Password:

acalabrutinib

This page shows the latest acalabrutinib news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn

AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn

Following AZ’s success with Calquence (acalabrutinib) – a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor – TNB-486 will further diversify the company’s haematology pipeline that have the potential

Latest news

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...